Wells Fargo Maintains Equal-Weight on Tandem Diabetes Care, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen has maintained an Equal-Weight rating on Tandem Diabetes Care (NASDAQ:TNDM) but lowered the price target from $40 to $30.
August 04, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Tandem Diabetes Care but lowered the price target from $40 to $30.
The lowering of the price target by Wells Fargo indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Tandem Diabetes Care's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100